Skip to content

Author

Clint A. Stalnecker

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A041: KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

KRAS is the dominant oncogene in pancreatic ductal adenocarcinoma (PDAC), mutated in ∼90% of tumors, and required for tumor initiation and tumor maintenance. The overall 5-year survival rate of PDAC remains a dismal ∼10%, underscoring an unmet need to develop novel therapies to ultimately improve patients’ outcomes....

Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al. · 0 citations
Aug 2026

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer

Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.

Yan-Pang Ching, Shruthi Narayanan, Jeffrey A. Klomp et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.